The document of under -use and discrepancy in genetic tests for breast and ovarian cancer patients documents document.
BRCA 1 And BRCA 2 For,,,,,,,,,, for,, for,,,, for,,,, for,,, for,,,, for,,,, for,,,, for,,, for,,, for,,, for,,, for,,,, for,,, for,,, for,,,, for,,, for,,,, for,,, for,,, for,,,, for,,, for,,, for,,,, for,,, for,,,, for,,, for,,,, for,,, for,,,, for,,, for,,,, for,,,, for,,,, for,,,, for,,,, for,,,, for,,,, for,,, for,,, for,,, for,,, for,,,,, for,,,, for,,,, for,,,, for,, for,.BRCA) Genetic testing is supported by clinical guidelines to inform the risk of hereditary cancer for people with some personal or family health history of breast, ovarian, pancreas, or prostate cancer, and guidance of these cancer treatments.
- The United States Prevention Services Task Force (USPSTF) recommends that the basic care providers use available tools of risk diagnosis to identify women at risk. BRCA Variations that should be obtained by genetic consultation and, if indicated after consultation, genetic testing.
- Leadership of National Comprehensive Cancer Network Practice suggests BRCA Genetic testing for people with specific personal and family history of cancer.
- US Food and Drug Administration (FDA) has approved BRCA Genetic test fellow diagnosis as poly adenosine diphosphate – ribos polymers (PARP) to guide cancer treatment with stopping.
CDC Office of Genomix & Prabstan Names some of the Public Health Applications BRCA Genetic testing as a tire 1; That is, if the help of scientific evidence to improve health results is effective and equally implemented. Tire 1 BRCA Genetic testing applications follow the USPSTF guide posts for hereditary breast and ovarian cancer (HBOC) risk diagnosis and FDA -approved fellow diagnosis. Differences in use BRCA The tests are associated with a number of factors, especially in all population groups that are medically low. Two recent studies have been permanently highlighted in low use and disparity BRCA Testing in breast and ovarian cancer patients.
Genetic testing under -use and health disparity
A recent nationwide study assessed the use of germs BRCA In people with ovarian cancer tests and a sub -sets of HBOC -affiliated breast cancer that are eligible BRCA According to clinical guidelines, testing, including breast cancer, diagnosed before the age of 45, triple -negative breast cancer before the age of 60 in women, or breast cancer in men. The study used electronic health records (EHR) nationwide. From January 2011 to March 2020, 56 % of breast cancer patients and 35 % of ovarian cancer patients conduct genetic examination within a year of cancer diagnosis. Use BRCA During the study years, testing increased significantly (37 % to 68 % for breast cancer, 23 % to 53 % for ovarian cancer), with genetic testing in ovarian cancer patients after the approval of PARP prevention. Medicare of breast cancer was less likely to take advantage of BRCA Genetic tests compared to beneficiaries from the trade health plan. The African American generation was associated with lower rates BRCA Use of tests in ovarian cancer patients. Was associated with older rates of older BRCA Use tests in breast or ovarian cancer patients.
Another recent study uses population -based cancer registry data that are linked to genetic testing laboratory data that patients diagnose cancer between 2013 and 2019 in California and Georgia diagnosis of cancer. In HBOC cancer patients, according to clinical guidelines, in cancer patients, 39 % of male breast patients are in need of male breast patients. BRCA Testing within 2 years of diagnosis. Older and African American, Asian, or Spanish breeds were associated with low rates of use of genetic tests.
Monitor of use and disparity in genetic testing
Both studies show the importance of population level data to track the implementation, results and progress in the genomic medicine. Studies also show how diverse data sources, such as state -based cancer registry, laboratory, EHR, administrative claims, and survey data, with their own strength and limits, are used to help create the basis for the use of genetic testing and discrepancy.
Administrative claims have numerous powers, such as large sample size, permanent information for entries, and detailed record of the use of health care services. However, the accuracy of the procedure codes and diagnostic code may vary, which can complicate the diagnosis of factors that affect the use of genetic tests. Adding EHR data to claims can provide more information to verify data diagnosis and procedure codes, such as cancer phase in diagnosis and imaging results. Compared to claims of claims, EHR can provide information about the use of clinical decision -making and health care services BRCA Testing or genetic testing. However, both claims and EHR figures may lack some necessary information to evaluate differences in sects, such as race/race, income and education levels.
Survey data, such as the use of National Health Interview Survey (NHIS) BRCA Test survey data, especially national data, such as NHIS and National Trends Survey Survey (Indicators) powers (indicators) include representing the general US population representative and assessing the differences in key sub -groups, which used self -reported settlement information, such as generation/generation, income, and education levels. However, it is important to acknowledge that most national survey data, including NHIS, is proportional in nature. To this extent, intervention and health results can be limited to such an extent.
Proceed to: Data for action
In spite of growing BRCA More efforts are needed to use tests, to ensure global access to qualified and increase tests. Though BRCA Testing, when used as a prevention service according to USPSTF recommendations, is covered by non -grandfather insurance providers without the protection of patients under the cost of safety and affordable care acts, then follow -up interference is not always through insurance. The financial burden of genetic testing and modern precautions can be important for patients, payers and healthcare systems. Golds Berry and his colleagues indicated that about 50 % of patients need financial aid programs to access PARP stop treatment. As if BRCA The use of test use and prevention continues to expand, the ongoing implementation research is very important to identify the diverse needs of the population, inform and expand the intervention. BRCA Use of tests and precautionary treatment.
